





















Multiple peptide hormones produced within the 
gastrointestinal system act also in the central nervous 
system and aid in the regulation of energy homeostasis and 
metabolism. The list of these peptides is progressively 
increasing and includes glucagon-like peptide 2 (GLP-2) 
as an anorexigenic factor.  GLP-2 is released from 
enteroendocrine L-cells following food intake and its 
principal target is represented by the gastrointestinal tract.  
GLP-2 has been shown to be an important intestinotrophic 
factor that stimulates epithelial cell proliferation and 
inhibits apoptosis. GLP-2 increases intestinal blood flow 
and the activity and expression of epithelial brush-border 
digestive enzymes and nutrient transporters, and 
consequently increases the intestinal digestive and 
absorptive capacity.  It inhibits gastric and intestinal 
motility, thus providing another mechanism to increase 
absorption of nutrients. Current research has focused on 
determining its physiological actions and its biological 
mechanisms in the gut, while very little is known on the 
GLP-2 actions within the brain. This review provides an 
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In the last decades a wealth of data has expanded 
our knowledge on the glucagon-like peptide 2 (GLP-2) 
as important molecule involved in a wide variety of 
functions. GLP-2 was first discovered as an 
intestinotrofic factor in 19961, but today it is 
recognized as a pleiotropic hormone that exerts 
different actions, not only in the gastrointestinal tract 
but also in the central nervous system. Since the 
biological actions of GLP-2 converge at multiple 
levels on the regulation of nutrient assimilation and 
energy homeostasis, a great deal of interest has been 
generated for drug development with therapeutic 
potential. The aim of this review is to explore recent 
advances in our understanding of GLP-2 biology.  
Synthesis, secretion and degradation  
GLP-2 is a 33-amino-acid peptide, which is 
derived from the cleavage of proglucagon, a large 
prohormone that is mainly expressed in cells of the 
endocrine pancreas, in the enteroendocrine L-cells, 
most of which are located in the distal ileum and colon, 
in the brain. Alternative splicing of proglucagon 
through prohormone convertases leads to the tissue-
specific release of GLP-2 and other peptides with 
diverse biological properties. In particular, in 
pancreatic alpha-cells proglucagon is cleaved by 
prohormone convertase (PC)-2 to form glucagon, the 
major glucagon fragment and intervening peptide (IP)-
1. In the gastrointestinal tract and in the brain, 
processing of proglucagon, which is operated by 
PC1/3, results in glucagon-like peptide-1 (GLP-1), 
GLP-2, IP2, oxynthomodulin and glicentin2.  GLP-2 is 
released in response to stimulation by luminal nutrient, 
including glucose, fatty acids and dietary fiber.  
 
After ingestion of nutrients, plasma levels of GLP-
2 increase 2- to 5-fold, depending upon the size and 
nutrient composition of the meal. It has been supposed 
that the peptide diffuse across the subepithelial 
lamina propria to activate afferent nerves and/or to 
enter the circulation, thus it may act also as paracrine 














GLP-2 structure is highly conserved across different 
mammalian species. It contains an alanine residue at 
position 2, rendering it ideal substrate for cleavage and 
inactivation by the enzyme dipeptidil peptidase 4 (DPP-
IV) and resulting in the generation of inactive GLP-2 3,33,3. 
The degradation by DDP-IV has important consequences. 
First of all, the half life of intravenous GLP-2 is very short, 
about 7 min in healthy humans4 and secondly, use of DPP-
IV inhibitors or the substitution of alanine with glycine as 
in tedugludide avoids  degradation and confers greater 
biological activity 5.  
GLP-2 receptor 
GLP-2 effects are mediated by the interaction with a 
specific GLP-2 receptor (GLP-2R), which is a G protein-
coupled receptor expressed mainly in the gut and in the 
brain. GLP-2R expression is restricted to the 
gastrointestinal tract and central nervous system, with 
limited expression in lung, cervix, and vagal afferents6-9. 
Multiple experimental approaches have localized the GLP-
2R to regions within the rodent central nervous system 
(CNS) including the hippocampus, hypothalamus and 
nucleus of the solitary tract in the mouse10. The exact 
cellular localization of the GLP-2R in the gut has been a 
source of controversy which is probably derived from 
methodological problems or species-specific expression. 
GLP-2R may be present in enteroendocrine cells7,11, 
enteric neurons12-14 and subepithelial myofibroblasts15, but 
in murine gastrointestinal tract GLP-2R is expressed 
exclusively in neurons and myofibroblasts, and it is not 
present at mucosal level7,12.  
 
In mouse, GLP-2R-mRNA has been demonstrated 
with high levels of expression in the bowel7 and recently 
GLP-2R protein has been demonstrated throughout the 
gastrointestinal tract, with higher expression in gastric 
fundus and colon14. The relative high prevalence of the 
GLP-2R in the gut might explain why, to date, GLP-2-
mediated effects have been observed almost exclusively in 
the GI tract 7. 
 
Actions of GLP-2 within the gastrointestinal tract 
The main biological effects of GLP-2 are related to the 
regulation of energy absorption and maintenance of 
mucosal morphology, function, and integrity16.  Central to 
the beneficial effects of GLP-2 on the gut is its biological 
action to increase intestinal growth, due to the 
enhancement of crypt cell proliferation and inhibition of 
apoptosis, resulting in expansion of villous height1.  In fact, 
a large number of studies have demonstrated that 
exogenously-administered GLP-2 is tropic for the small 
intestine and, to a lesser extent, the colon1,15,17. However, 
endogenous GLP-2 plays a role in the adaptative intestinal 
growth that occurs in rodents in response to oral re-
feeding after a period of nutrient deprivation, as shown 
by using GLP-2 3,33 or GLP-2R knock out mice18-20. 
The association between GLP-2 and intestinal 
growth/adaptation is most evident in a variety of 
pathological conditions, including post-resection 
intestinal adaptation, celiac disease, parenteral 
nutrition-induced intestinal atrophy and inflammatory 
bowel disease16.   
GLP-2 is able to maintain mucosal integrity by 
enhancing intestinal barrier function and decreasing 
transcellular and paracellular epithelial permeability21. 
The ability of GLP-2 to increase barrier function has 
been confirmed in non-obese diabetic and ob/ob obese 
murine models22. In fact, administration of a prebiotic 
to ob/ob mice induces GLP-2-dependent up-regulation 
of the tight junction proteins, zonuline-1 and 
occludin22. In addition, GLP-2 acts in 
pathophysiological states as an anti-inflammatory 
agent, reducing intestinal mucosal inflammatory 
cytokine production23. 
 
GLP-2 exerts numerous other actions within the 
GI tract to promote energy absorption. It increases the 
uptake of luminal nutrients, including sugars and lipids, 
by augmenting the activity and the expression of 
nutrient transporters and the expression of different 
enzymes involved in digestion16. GLP-2 is able also to 
increase the mesenteric blood flow13. GLP-2 has also 
been shown to inhibit gastric acid hypersecretion24 and 
the intestinal chloride secretion25. 
 
Figure 1: Increase in gastric volume induced by GLP-2 
might represent satiety signaling to the central nervous 
system through the activation of stretch receptors and 
afferent nerves 
GLP-2 inhibits GI motility, thus providing another 













nutrient. Specifically, GLP-2 reduces the vagally-induced 
antral motility in pigs26 and it decreases the mouse gastric 
fundic tone leading to an increase of stomach capacity27. 
Although it is not clearly established if the GLP-2 effect 
on mouse gastric stomach is physiological or 
pharmacological, the GLP-2 action on gastric fundus 
seems particularly interesting, because it could represent a 
satiety signaling which well fits with the finding that GLP-
2 is a chemical mediator inhibiting rodent feeding 
behaviour28. In fact, increase in the gastric volume might 
mean activation of stretch receptors and greater satiety 
signals to the brain (Fig.1), but electrophysiological 
experiments in vivo are necessary to confirm this 
hypothesis.  
In mouse GLP-2 inhibits the intestinal transit in vivo29 
and it reduces spontaneous or electrically-evoked 
cholinergic contractions of the small and large intestine in 
vitro14,30. The peptide modulation on the gastrointestinal 
motility may be due to central nervous mechanisms26, but 
involvement of the enteric nervous system has been also 
clearly shown through the in vitro studies14,27,30.  As GLP-
2R is expressed in the subepithelial myofibroblasts and 
enteric nervous system as well as human enteroendocrine 
cells, it has been proposed that the peptide exerts its 
actions indirectly via downstream mediators deriving from 
GLP-2R-expressing cells7. Indeed, neural VIP, nitric oxide 
and reduction of the acetylcholine release from enteric 
nerves have been reported to be involved in the inhibitory 
motor effects induced by GLP-2 in different regions of the 
mouse GI tract14,27,30. However determining how GLP-2 
produces its biological effects, which mediators are 
involved and how these mediators interact is an area of 
intense research31 and the reader is referred to a recent 
paper for a more detailed overview 32.  
Extraintestinal actions of GLP-2 
GLP-2 may be considered an anorexigenic peptide 
because intracerebroventricular administrations of GLP-2 
reduce the food intake in rodents8,28. Interestingly, in rats 
the anorectic response to GLP-2 seems to depend on a 
certain tone of central GLP-1 receptors because 
pharmacological antagonism of GLP-1 receptors by prior 
administration of exendin(9–39) abolishes GLP-2 induced 
anorexia28. On the contrary studies in mice have pointed to 
the opposite: Blocking central GLP-1 receptors with 
exendin-9 increases GLP-2 induced anorexia8. Further 
studies focusing on the role of central GLP-2 receptors in 
appetite regulation are clearly needed. On the other hand, 
multiple experimental approaches have localized the GLP-
2R to regions within the rodent CNS including the 
hypothalamus and hippocampus10. Activation of the GLP-
2R in the hypothalamus may be responsible for the effects 
of central GLP-2 administration on feeding behaviour and 
because the hippocampus is sensitive to hunger and 
satiety signals, might influence appetitive behaviour 
through inhibitory learning and memory process. 
However, up to date studies in humans have not 
demonstrated decrease in the food intake after 
peripheral GLP-2 administration33,34, even if recent 
data have shown that intraperitoneal injections of 
teduglutide reduce food intake in mouse, suggesting a 
role for GLP-2 in the short-term regulation of the 
ingestive behaviour35.  
 
 In general, very few studies have been conducted 
to elucidate the roles of the GLP-2 in the central 
nervous system36. Consistent  with a general 
cytoprotective effect of GLP-2 within the GI mucosa,  
the few studies have suggested that activation of GLP-
2 receptors can protect neurons from excitotoxic 
damage36. More specifically, GLP-2 has been reported 
to reduce glutamate-induced cell death in cultured 
hippocampal cells10 and to stimulate the proliferation 
of rat astrocytes 37,38. Antidepressant-like effects of 
GLP-2 that occur via monoamine pathways have also 
been noted in mice, but this has yet to be confirmed39. 
 
Conclusions and future directions 
All the actions described make GLP-2 an 
attractive drug for the treatment or prevention of 
gastrointestinal disease in human subjects. However,  
because very few studies have been conducted to 
elucidate the roles of this peptide in central nervous 
system, we are still far from having an in depth 
understanding of the complex neurobiology of GLP-2. 
Therefore, future research efforts should aim at 
providing new information on the roles subserved by 
GLP-2 within the brain.  
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